Zynex (ZYXI) Change In Working Capital : $5.8 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Zynex Change In Working Capital?

Zynex's change in working capital for the quarter that ended in Mar. 2024 was $0.4 Mil.

Zynex's change in working capital for the fiscal year that ended in Dec. 2023 was $5.9 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Zynex Change In Working Capital Historical Data

The historical data trend for Zynex's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Change In Working Capital Chart

Zynex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-5.18

-12.22

-15.22

-9.10

5.89

Zynex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															0.47	-2.03	3.81	3.63	0.41

Zynex Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.8 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Zynex Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Zynex's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zynex (ZYXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

9555 Maroon Circle, Englewood, CO, USA, 80112

Website

https://www.zynex.com

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.

Executives

Daniel J Moorhead	officer: Chief Financial Officer	9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok	officer: See Remarks	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard	director, 10 percent owner, officer: President, CEO and Chairman	10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery	officer: See Remarks	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow	director	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress	director	3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc	10 percent owner	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea	officer: Chief Operating Officer	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112